Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M340Revenue $M12.0Net Margin (%)-116.9Z-Score0.8
Enterprise Value $M307EPS $-2.9Operating Margin %-75.9F-Score4
P/E(ttm))0Cash Flow Per Share $0Pre-tax Margin (%)-69.0Higher ROA y-yY
Price/Book10.110-y EBITDA Growth Rate %0Quick Ratio3.2Cash flow > EarningsY
Price/Sales5.95-y EBITDA Growth Rate %0Current Ratio3.8Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-52.7Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-204.1Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M42.1ROI % (ttm)-96.2Gross Margin Increase y-yN

Gurus Latest Trades with SUPN

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found!

SUPN is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


SUPN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Bhatt Padmanabh P.Sr. VP of IP; CSO 2013-08-19Sell2,285$8.210.37 view
BIGHAM MICHAELDirector 2013-03-22Buy35,000$5.4152.31 view
SIEBERT JOHN MDirector 2013-03-21Buy3,000$5.549.82 view
Khattar Jack A.President, CEO 2013-03-15Buy10,000$6.1533.98 view
PATRICK GREGORY SVP, CFO 2013-03-14Buy5,000$6.9518.56 view
ORBIMED ADVISORS LLC10% Owner 2013-02-13Sell302,183$7.559.14 view
ORBIMED ADVISORS LLC10% Owner 2012-12-18Sell297,815$6.9219.08 view
SIEBERT JOHN MDirector 2012-12-04Buy7,000$8.141.23 view
Abingworth Management LTD10% Owner 2012-05-04Buy1,100,000$564.8 view
ORBIMED ADVISORS LLCDirector, 10% Owner 2012-05-04Buy1,100,000$564.8 view

Press Releases about SUPN :

    Quarterly/Annual Reports about SUPN:

    News about SUPN:

    Articles On GuruFocus.com
    Supernus Pharmaceuticals Reports Insider Buys Mar 26 2013 

    More From Other Websites
    SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers,... Sep 18 2014
    Others Overlooked Supernus Pharmaceuticals (SUPN), Should You Buy It Now? Sep 10 2014
    SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 08 2014
    Supernus Announces Issuance of Fourth US Patent Protecting Oxtellar XR(R) Sep 04 2014
    Why You Shouldn't Bet Against Supernus Pharmaceuticals (SUPN) Stock Sep 04 2014
    SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 25 2014
    Supernus' Trokendi XR Faces Generic Threat from Actavis Aug 22 2014
    The Zacks Analyst Blog Highlights: Johnson & Johnson, Tekmira Pharmaceuticals, Gilead Sciences,... Aug 21 2014
    Supernus Announces Paragraph IV ANDA Filing for Trokendi XR(R) Aug 21 2014
    SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 20 2014
    SUPERNUS PHARMACEUTICALS INC Financials Aug 20 2014
    Supernus to Attend FBR HealthCare Conference in September Aug 19 2014
    Supernus's SPN-810 Gets Fast Track Status for ADHD Aug 18 2014
    Others Overlooked Supernus Pharmaceuticals (SUPN), Should You Buy It Now? Aug 18 2014
    Supernus Receives FDA Fast Track Designation for SPN-810 Aug 14 2014
    SUPERNUS PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Aug 12 2014
    Supernus (SUPN) Posts Strong Earnings in Q2, Guidance Raised Aug 12 2014
    SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 11 2014
    Supernus Announces Second Quarter 2014 Results Aug 11 2014
    Q2 2014 Supernus Pharmaceuticals Earnings Release - After Market Close Aug 11 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK